Aricept

Pre-clinicalCompleted

1 views this week 0 watching💤 Quiet

Interest: 26/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Alzheimer's Disease

Conditions

Alzheimer's Disease

Trial Timeline

Mar 1, 2015 → Jun 1, 2016

NCT ID

NCT02158910

About Aricept

Aricept is a pre-clinical stage product being developed by Eisai for Alzheimer's Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT02158910. Target conditions include Alzheimer's Disease.

What happened to similar drugs?

20 of 20 similar drugs in Alzheimer's Disease were approved

Approved (20) Terminated (2) Active (0)

✅Alfoatirin® Tab. + Aripezil® Tab. + Aripezil® Tab.YuhanApproved

✅DonepezilEisaiApproved

✅DONEPEZIL HYDROCHLORIDEEisaiApproved

✅Donepezil HCLEisaiApproved

✅Donepezil HClEisaiApproved

✅Donepezil HydrochlorideEisaiApproved

✅AriceptEisaiApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (4)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02158910	Pre-clinical	Completed	Mar 1, 2015	Jun 1, 2016	Alzheimer's Disease
NCT00230568	Approved	Completed	Dec 1, 2005	Dec 1, 2007	Alzheimer's Disease
NCT00103948	Phase 2	Completed	Feb 1, 2005	Feb 1, 2007	Cognitive Impairment
NCT00165815	Phase 3	Completed	Aug 1, 2002	Jul 1, 2005	Dementia With Parkinson's Disease

Competing Products

20 competing products in Alzheimer's Disease

See all competitors

Product	Company	Stage	Hype Score
LY450139 + Placebo	Eli Lilly	Phase 3	40
Solanezumab + Placebo	Eli Lilly	Phase 3	32
LY450139 dihydrate + placebo	Eli Lilly	Phase 2	35
GSK4527226	Alector	Phase 2	29
GSK4527226	Alector	Phase 2	32
AL002	Alector	Phase 2	17
Solanezumab + Placebo	Eli Lilly	Phase 3	32
simufilam	Cassava Sciences	Phase 2	17
Remternetug + Placebo	Eli Lilly	Phase 3	44
solanezumab	Eli Lilly	Phase 2	35
LY2886721 + Placebo	Eli Lilly	Phase 1	29
Gantenerumab + Gantenerumab + Gantenerumab + Placebo	Chugai Pharmaceutical	Phase 1	29
Alfoatirin® Tab. + Aripezil® Tab. + Aripezil® Tab.	Yuhan	Approved	39
FK962	Astellas Pharma	Phase 2	27
ASP0777 + Placebo	Astellas Pharma	Phase 1	29
Elenbecestat + Placebo	Eisai	Phase 3	32
Donepezil	Eisai	Approved	43
Aricept (donepezil SR 23 mg) + Aricept (donepezil IR 10 mg)	Eisai	Phase 3	40
Donepezil hydrochloride	Eisai	Phase 3	40
Donepezil Hydrochloride	Eisai	Pre-clinical	26